Related Experiment Video
Updated: Aug 15, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Multidisciplinary supportive care in cancer: cost analysis
Daniel Monnery1, Yan Liu2, Ann Griffiths3
1Palliative Medicine, Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, UK daniel.monnery@nhs.net.
Purpose:
Enhanced supportive care (ESC) is the early implementation of supportive care in cancer. In England, this model is being developed to support patients with treatable but not curable cancer and implements a multiprofessional approach.
Objective:
To describe the workforce and cost-effectiveness of an outpatient ESC service in a tertiary cancer centre in England.
Methods:
Workforce costs to deliver ESC to 265 patients was collected. Service impact on secondary care usage in the last year of life was compared against the regional and national average derived from the National Health Service Digital Secondary Uses Service dataset.
Results:
Our ESC service required the input of seven professional groups and cost £125 542 for 12 months. ESC patients had an average of 1.72 fewer admissions per patient per last year of life than the national average. Length of stay was reduced from an average of 9.2 days to 4.78 days per admission in the last year of life. The reduced secondary care usage saved £2 398 537.68.
Conclusions:
Outpatient ESC in this cohort required an multidisciplinary team approach and saved money through secondary care use reduction.
More Related Videos
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
Cancer Survival Analysis
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Chronic Kidney Disease III: Interprofessional Care